HC Wainwright Issues Negative Forecast for SGMO Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – HC Wainwright decreased their Q4 2025 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report released on Monday, April 7th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.38 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million.

Other research analysts also recently issued reports about the company. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Wells Fargo & Company cut their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Finally, Truist Financial lowered their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $0.70 on Wednesday. The company’s 50-day simple moving average is $0.94 and its two-hundred day simple moving average is $1.39. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The company has a market capitalization of $157.00 million, a P/E ratio of -0.93 and a beta of 1.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. E Fund Management Co. Ltd. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $25,000. JPMorgan Chase & Co. boosted its position in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Sangamo Therapeutics during the 4th quarter valued at about $28,000. Finally, Shelton Wealth Management LLC acquired a new position in Sangamo Therapeutics during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.